INTRODUCTION {#S1}
============

Myocarditis remains a leading cause of heart failure (HF) in children and young adults ([@R14]; [@R23]). A recent global estimate of myocarditis incidence is approximately 1.5-million cases annually ([@R50]). However, the actual myocarditis incidence could be significantly underestimated due to the heterogeneous clinical manifestations and a wide spectrum of disease presentations ([@R30]). Between 9% and 16% of patients with myocarditis develop dilated cardiomyopathy (DCM). Yet no biomarkers are currently available to identify myocarditis patients at risk of developing DCM ([@R28]; [@R44]; [@R59]). To date, treatment of myocarditis and prevention of its sequelae, DCM, remain vital goals in the quest to reduce morbidity and mortality in patients.

In the experimental autoimmune myocarditis (EAM) model as well as human clinical studies, we and others have reported that monocytes and macrophages comprise approximately three-quarters of the infiltrating cells in the injured myocardium ([@R10]; [@R87]). Cardiac tissue-resident macrophages originate from precursors that develop in the embryonic yolk sac and fetal liver and maintain locally as self-renewing populations to perform tissue-specific functions. After birth, a proportion of embryonically derived cardiacresident macrophages are progressively replaced by monocyte-derived macrophages (MDMs) that originate in the bone marrow (BM) ([@R26]; [@R33]; [@R36]; [@R65]; [@R79]; [@R93]). BM-derived circulating monocytes in mice consist of two subsets: the "classical" inflammatory Ly6C^hi^ monocytes and the "non-classical" patrolling Ly6C^lo^ monocytes. The former resemble human CD14^hi^CD16^−^ and/or CD14^+^CD16^+^ monocytes, while the latter have similar characteristics to human CD14^−^CD16^hi^ monocytes ([@R17]; [@R31]; [@R32]; [@R48]; [@R49]; [@R83]; [@R85]; [@R96]). Cardiac injury triggers massive Ly6C^hi^ monocytes mobilization, trafficking, and extravasation into the heart, where they promote inflammation associated with tissue repair and remodeling ([@R13]; [@R25]; [@R55]; [@R77]; [@R26]; [@R38]; [@R41]).

It is challenging to distinguish tissue-resident macrophages from recruited MDMs when they co-exist in the same inflammatory niche. Ly6C^hi^ monocytes are known precursors to cardiac macrophages during cardiac injury ([@R26]; [@R69]). However, the contribution of patrolling Ly6C^lo^ monocytes to the macrophage pool is controversial. Ablation of Ly6C^lo^ monocytes in a mouse model of myocardial infarction (MI) resulted in depletion of other monocyte and macrophage populations ([@R69]). Moreover, it is unclear whether the phenotype and function of either Ly6C^hi^ or Ly6C^lo^ MDMs differ from one another. The mechanism through which extrinsic stimuli influence monocytes survival, proliferation, differentiation, and function in the context of cardiac damage and inflammation is not understood.

We previously identified an important role of IL-17A in driving myocarditis progression to DCM ([@R9]). IL-17A-deficient or IL-17 receptor alpha (IL17Ra)-deficient mice developed myocarditis with similar severity as wild-type (WT) animals. Remarkably, they have preserved cardiac functions and were protected from myocardial fibrosis and DCM ([@R9]). We also reported that anti-IL-17A treatment during EAM onset can prevent DCM development in WT mice ([@R9]). IL-17A signaling to cardiac fibroblasts results in the induction of granulocyte-macrophage colony-stimulating factor (GM-CSF) and CCL2, which drives Ly6C^hi^ monocyte chemotaxis and accumulation in the heart, worsening DCM outcomes ([@R91]; [@R9]). The pathogenic role of IL-17A in the development of cardiac fibrosis and HF has also been confirmed in MI ([@R18]).

To better understand the underlying mechanisms of how recruited monocytes drive DCM, we fate-mapped the accumulating monocyte subsets in the heart during myocardial inflammation. We found that IL-17A-activated cardiac fibroblasts significantly arrested Ly6C^lo^ monocyte-to-macrophage differentiation and proliferation. We also discovered that IL-17A signaling through cardiac fibroblasts can downregulate efferocytosis receptors expressed by Ly6C^hi^ MDMs, negatively affecting their phagocytic function during inflammation resolution. Furthermore, both intrinsic and extrinsic factors modulate distinct transcriptomic profiles of Ly6C^hi^ and Ly6C^lo^ MDMs, signifying their potential functional differences in the context of myocarditis. Our work provides evidence that cardiac fibroblasts play a decisive role in MDM ontogeny and function during cardiac injury. Our findings provide insights into monocyte and macrophage biology and their roles in the context of chronic cardiac inflammation.

RESULTS {#S2}
=======

Infiltrating Monocytes Contribute to Three Subsets of Macrophages during Myocarditis {#S3}
------------------------------------------------------------------------------------

We created parabiotic mice to elucidate the contribution of infiltrating monocytes to cardiac macrophage populations during myocarditis development. The circulations of CD45.1 and CD45.2 mice were surgically joined, and EAM was induced in CD45.1 mice 2 days prior to parabiosis ([Figure 1A](#F1){ref-type="fig"}). On day 21 of EAM, we confirmed by histology that only CD45.1 parabionts developed severe myocardium infiltration ([Figure 1B](#F1){ref-type="fig"}). Flow cytometric analysis showed a significantly elevated total number of infiltrating non-neutrophilic myeloid cells in the CD45.1 EAM hearts compared to their CD45.2 parabiotic partners ([Figure 1C](#F1){ref-type="fig"}). We also observed that CD45.1 EAM hearts had more total F4/80^hi^CD64^+^ macrophages compared to non-EAM CD45.2 hearts, indicating cardiac macrophage expansion in response to inflammation ([Figure 1D](#F1){ref-type="fig"}). We found a higher frequency of CD45.2^+^ MDMs in the CD45.1 EAM mice, compared to CD45.1^+^ MDMs in the CD45.2 non-EAM mice ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}; see the gating strategy in [Figure S1A](#SD1){ref-type="supplementary-material"}). However, a higher frequency of CD45.2^+^ MDMs in the CD45.1 EAM mice did not reflect the increase in infiltrating monocyte populations ([Figure 1E](#F1){ref-type="fig"}). In addition, the heart Ly6C^hi^-to-Ly6C^lo^ monocyte ratio between parabionts did not differ significantly ([Figure 1G](#F1){ref-type="fig"}). Resident tissue macrophages can be further divided into three subsets, based on their expressions of CCR2 and MHCII ([@R26]). We found that infiltrating CD45.2^+^ monocytes predominantly differentiated into CCR2^+^MHCII^+^ macrophages, though they possess the capacity to replenish all three macrophage subsets in the EAM hearts ([Figures 1E](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}). However, the heart-infiltrating CD45.1^+^ monocytes in the non-EAM CD45.2 mice differentiated only into MHCII^+^ macrophages ([Figures 1E](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}). Taken together, our data support the idea that during cardiac inflammation infiltrating monocytes readily differentiate into macrophages and these monocyte-derived cells can replenish all three macrophage subpopulations.

During cardiac inflammation, mature Ly6C^hi^ monocytes arise from common monocyte progenitors (cMoPs) in the BM before trafficking to the heart ([@R39]). We examined the mature monocyte population in the BM in response to cardiac inflammation (see the gating strategy in [Figure S1B](#SD1){ref-type="supplementary-material"}). We found a substantial presence of CD45.1^+^-grafted cells in the CD45.2 parabiont BM, whereas CD45.2^+^ monocytes were relatively rare in the CD45.1 EAM parabiont BM ([Figures S1C](#SD1){ref-type="supplementary-material"} and [S1D](#SD1){ref-type="supplementary-material"}). We speculated that this could be due to undifferentiated CD45.1^+^ Ly6C^hi^ monocytes homing back to the CD45.1 BM in the absence of inflammation ([@R85]). Alternatively, a systemic response to adjuvants used for EAM induction in CD45.1^+^ parabionts could increase monocyte infiltration into non-EAM parabiont BM. Another possible explanation is that EAM BM is saturated with inflammatory cells, which prevented CD45.2^+^ monocytes from infiltrating CD45.1 BM. Nevertheless, the ratio of Ly6C^hi^-to-Ly6C^lo^ monocytes was highly comparable between parabionts in the BM ([Figure S1E](#SD1){ref-type="supplementary-material"}). Collectively, the similarity of monocyte ratios in the BM between EAM and naive mice suggests the local cardiac inflammatory milieu is instrumental in monocyte-to-macrophage differentiation in the heart.

Cardiac Fibroblasts Facilitate Ly6C^hi^ and Ly6C^lo^ Monocyte-to-Macrophage Differentiation {#S4}
-------------------------------------------------------------------------------------------

The results from the parabiosis experiments suggested that MDMs in an inflamed cardiac environment are a highly heterogenous population. Whether macrophage heterogeneity is instigated by monocyte intrinsic differences and/or extrinsic environmental factors is not yet known. Cardiac fibroblasts play a key sentinel role during myocarditis as they produce myelotropic chemokines and cytokines such as GM-CSF and CCL2 ([@R9]; [@R91]). This immune modulatory property of cardiac fibroblasts was also confirmed in MI and Kawasaki disease ([@R3]; [@R18]). To examine whether Ly6C^hi^ and Ly6C^lo^ monocytes can differentiate into macrophages and whether cardiac fibroblasts facilitate this differentiation process, we established an *in vitro* co-culture system. We harvested primary cardiac fibroblasts from naive WT mice and co-cultured them with fluorescence-activated cell sorting (FACS)-sorted IL-17Ra^−/−^ EAM splenic Ly6C^hi^ or Ly6C^lo^ monocytes for up to 160 h ([Figure 2A](#F2){ref-type="fig"}; see the sorting strategy in [Figure S2A](#SD1){ref-type="supplementary-material"}). Due to the relative paucity of monocytes in blood, we used spleens as a surrogate source of monocytes. Flow cytometric analysis showed that approximately 80% of the Ly6C^hi^ monocytes quickly differentiated to MDMs, while almost all Ly6C^lo^ monocytes remained undifferentiated over the first 40 h of culture ([Figures 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). However, when we assessed their phenotypic changes at 160 h, approximately 30% of the Ly6C^lo^ monocytes had become macrophages ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). Neither Ly6C^hi^ nor Ly6C^lo^ monocytes were able to survival long term nor differentiate into macrophages in the absence of cardiac fibroblasts ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). Ly6C^hi^ and Ly6C^lo^ MDMs were morphologically similar and resembled macrophages after 160 h of co-culture with cardiac fibroblasts ([Figure 2F](#F2){ref-type="fig"}). To better understand how monocytes and cardiac fibroblasts interact *in vitro*, we used live-cell time-lapsed imaging to track carboxyfluorescein succinimidyl ester (CFSE)-labeled (CFSE^+^) Ly6C^hi^ and Ly6C^lo^ monocytes co-cultured with CFSE^−^ cardiac fibroblasts. We found that CFSE^+^Ly6C^hi^ monocytes started to cluster around cardiac fibroblasts as early as 9 h into co-culture. They adhered strongly to the cardiac fibroblasts and became static when adhesions formed ([Figure 2G](#F2){ref-type="fig"}; [Video S1](#SD2){ref-type="supplementary-material"}). In contrast, CFSE^+^Ly6C^lo^ monocytes were motile and they formed transient clusters around cardiac fibroblasts. Ly6C^lo^ monocytes also lost CFSE at a higher rate, indicating faster proliferation when compared to Ly6C^hi^ monocytes ([Figure 2H](#F2){ref-type="fig"}; [Video S2](#SD3){ref-type="supplementary-material"}). Flow cytometric analysis confirmed that Ly6C^lo^ monocytes indeed proliferate faster than Ly6C^hi^ monocytes ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). Next, we used transmission electron microscopy (EM) to examine whether MDMs and cardiac fibroblasts establish cell-to-cell connections, which would suggest the presence of molecular adhesion structures. Both Ly6C^hi^ and Ly6C^lo^ MDMs contained numerous cytoplasmic electron-lucent vesicles ([Figures 2I](#F2){ref-type="fig"} and [2J](#F2){ref-type="fig"}). They each formed close cell-to-cell contact with cardiac fibroblasts ([Figures 2K](#F2){ref-type="fig"} and [2L](#F2){ref-type="fig"}). Interestingly, these close cell-to-cell interactions are important for driving monocyte-to-macrophage differentiation. We demonstrated a significant reduction in monocyte-to-macrophage differentiation when monocyte-fibroblast contacts are inhibited by a transwell barrier ([Figures S2D](#SD1){ref-type="supplementary-material"} and [S2E](#SD1){ref-type="supplementary-material"}). We also showed that Ly6C^hi^ monocytes induced cardiac fibroblasts to significantly upregulate *Ccl2* mRNA levels compared to Ly6C^lo^ monocytes, ensuring a feed-forward loop for a continuous supply of pro-inflammatory monocytes to accumulate in an inflamed microenvironment ([Figure S2F](#SD1){ref-type="supplementary-material"}). Taken together, Ly6C^hi^ and Ly6C^lo^ monocytes establish close physical contact with cardiac fibroblasts and these cell-to-cell interactions play a role in facilitating Ly6C^hi^ and Ly6C^lo^ monocytes survival and differentiation into macrophages.

Inflammatory Monocytes Are the Main Precursors for MDMs during Myocarditis in Both Mice and Humans {#S5}
--------------------------------------------------------------------------------------------------

We next sought to investigate whether both Ly6C^hi^ and Ly6C^lo^ monocytes could differentiate *in vivo* during EAM development. We FACS-sorted splenic CD45.2^+^Ly6C^hi^ or Ly6C^lo^ monocytes from WT mice on day 14 of EAM, and intracardially injected them into CD45.1 WT recipients at the peak of EAM ([Figure 3A](#F3){ref-type="fig"}). Both Ly6C^hi^ and Ly6C^lo^ monocytes and MDMs of the donor origin persisted in the myocardium 40 h after the injection ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). Approximately 50% of the injected Ly6C^hi^ monocytes had differentiated into F4/80^hi^CD64^+^ macrophages ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}), whereas less than 1% of the Ly6C^lo^ monocytes differentiated into macrophages ([Figures 3D](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}). We employed Barnes-Hut stochastic neighbor embedding (bhSNE) analysis to visualize monocyte-to-macrophage differentiation ([@R1]; [@R11]). We confirmed that CD45.2^+^Ly6C^lo^ monocytes were mostly unable to differentiate into macrophages, while CD45.2^+^ Ly6C^hi^ monocytes contributed significantly to the cardiac macrophage pool during EAM ([Figures 3G](#F3){ref-type="fig"} and [3H](#F3){ref-type="fig"}). We also examined Ly6C^hi^ and Ly6C^lo^ monocytes differentiation at 160 h *in vivo* and found that very few injected monocytes were present in the myocardium, indicating a high local turnover rate. Notably, we did not find evidence suggesting Ly6C^lo^ monocyte-to-macrophage differentiation (data not shown). Upon immunofluorescence examination of endomyocardial biopsy samples from a patient with giant cell myocarditis, we found the expression of CD68, a pan-macrophage marker, coincided with CD14 but not CD16. This suggests that the inflammatory CD14^+^CD16^−/+^ but not the patrolling CD14^−^CD16^+^ monocyte populations are the likely source of macrophages in giant cell myocarditis ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). In parallel, we examined endomyocardial biopsies from three patients who had left ventricular assist devices implanted as a result of HF with various etiologies ([Table S1](#SD1){ref-type="supplementary-material"}). Flow cytometric analysis from all three patients indicated that CD14^+^CD68^+^, but not CD16^+^CD68^+^, macrophages, are present in the heart ([Figure S3C](#SD1){ref-type="supplementary-material"}). This further supports the hypothesis that CD14^+^CD16^−^ monocytes are the main source of cardiac macrophages in human myocarditis. In conclusion, human CD14^+^ and mouse Ly6C^hi^ monocyte subsets are the major contributors to the cardiac macrophage population during myocarditis development.

IL-17A Signaling through Cardiac Fibroblasts Inhibits Ly6C^lo^ Monocyte-to-Macrophage Differentiation and Ly6C^lo^ Proliferation {#S6}
--------------------------------------------------------------------------------------------------------------------------------

EAM is a Th17-driven disease and IL-17A induces the production of myelotropic cytokines and chemokines by cardiac fibroblasts ([@R91]). The differentiation capacity of Ly6C^lo^ monocytes *in vivo* appeared to be limited, and we therefore speculated that IL-17A plays a role in determining monocyte fate during EAM. Since monocytes require cardiac fibroblasts to differentiate into macrophages, we co-cultured FACS-sorted IL-17Ra^−/−^ EAM Ly6C^hi^ and Ly6C^lo^ splenic monocytes with either cardiac fibroblasts alone or IL-17A-stimulated cardiac fibroblasts for 160 h. We found that IL-17A-stimulated cardiac fibroblasts significantly inhibited Ly6C^lo^ monocyte-to-macrophage differentiation, while its effect on Ly6C^hi^ monocyte differentiation was minimal ([Figure 4A](#F4){ref-type="fig"}). Using CFSE labeling, we found that proliferation of Ly6C^lo^ monocytes was almost completely inhibited by cardiac fibroblasts stimulated with IL-17A, whereas proliferation of Ly6C^hi^ monocytes was minimally affected ([Figure 4B](#F4){ref-type="fig"}). We described previously that cardiac fibroblasts are potent producers of GM-CSF upon IL-17A stimulation ([@R91]). We found that while treatment with recombinant GM-CSF only marginally suppressed Ly6C^hi^ monocyte-to-macrophage differentiation ([Figure 4C](#F4){ref-type="fig"}), it completely recapitulated the inhibitory effect of IL-17A through cardiac fibroblasts on Ly6C^lo^ monocyte-to-macrophage differentiation ([Figure 4D](#F4){ref-type="fig"}). IL-17A-induced inhibition of Ly6C^lo^ monocyte-to-macrophage differentiation could be reversed with anti-GM-CSF treatment ([Figure 4D](#F4){ref-type="fig"}). Similarly, GM-CSF did not change the proliferation of Ly6C^hi^ monocytes and MDMs, while completely inhibiting proliferation of undifferentiated Ly6C^lo^ monocytes ([Figures 4E](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"}). Treatment of anti-GM-CSF to IL-17A-stimulated cardiac fibroblasts restored proliferation of Ly6C^lo^ monocytes ([Figure 4F](#F4){ref-type="fig"}). We further validated all of our major *in vitro* findings using splenic monocytes from WT animals and showed that monocytes responded to environmental cues similarly regardless of their sources ([Figure S4](#SD1){ref-type="supplementary-material"}). To summarize, GM-CSF acts as a downstream mediator of IL-17A signaling, through cardiac fibroblasts, that exhibits minor inhibitory effects on Ly6C^hi^ monocyte differentiation and proliferation, but substantially inhibits Ly6C^lo^ monocyte differentiation and proliferation *in vitro*.

The Absence of IL-17A Signaling Enables Ly6C^lo^ Monocyte-to-Macrophage Differentiation *In vivo* {#S7}
-------------------------------------------------------------------------------------------------

We next aimed to test *in vivo* whether eliminating IL-17A signaling during EAM would enable Ly6C^lo^ monocytes to undergo differentiation. To begin, we intracardially injected either FACS-sorted CD45.2^+^Ly6C^hi^ or Ly6C^lo^ monocytes into CD45.1 IL17Ra^−/−^ recipients during the peak of EAM ([Figure 5A](#F5){ref-type="fig"}). Both monocyte subsets were present in the myocardium 40 h post injection ([Figures 5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}; see the monocyte gating strategy in [Figure S5A](#SD1){ref-type="supplementary-material"}). Strikingly, while most of the Ly6C^hi^ monocytes differentiated into macrophages, approximately 30% of the Ly6C^lo^ monocytes also differentiated into macrophages ([Figures 5D](#F5){ref-type="fig"}--[5F](#F5){ref-type="fig"}). The bh-SNE algorithm further confirmed a non-negligible proportion of Ly6C^lo^ MDMs ([Figures 5G](#F5){ref-type="fig"} and [5H](#F5){ref-type="fig"}). In addition, we examined whether the Ly6C^lo^ monocytes were able to traffic through blood and differentiate in the myocardium. We retro-orbitally injected FACS-sorted CD45.1^+^Ly6C^lo^ monocytes into either CD45.2 WT or IL17Ra^−/−^ recipients during the peak of EAM ([Figure 5I](#F5){ref-type="fig"}). CD45.1^+^Ly6C^lo^ cells were found in the myocardium 40 h post injection in both WT and IL-17Ra^−/−^ mice compared to mice with no adoptive transferred cells ([Figures 5J](#F5){ref-type="fig"} and [5K](#F5){ref-type="fig"}). Consistent to our finding, approximately 30% of the Ly6C^lo^ monocytes had differentiated into macrophages in IL17Ra^−/−^ recipients but not in WT ([Figures 5L](#F5){ref-type="fig"} and [5M](#F5){ref-type="fig"}). Therefore, our results indicate that the absence of IL-17A signaling enables Ly6C^lo^ monocyte-to-macrophage differentiation, again, underlining the inhibitory role of IL-17A on Ly6C^lo^ monocyte-to-macrophage differentiation.

Distinct Gene Expression Profiles in Ly6C^hi^ and Ly6C^lo^ MDM Subsets Differentiated *In vitro* in the Presence of Untreated or IL-17A-Treated Cardiac Fibroblasts {#S8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

To explore the molecular differences between these MDM subpopulations, we next characterized the changes in gene expression that occurred during Ly6C^lo^ and Ly6C^hi^ monocyte-to-macrophage differentiation after being co-cultured with cardiac fibroblasts (conditions 1 and 2). In addition, we also examined the effect of IL-17A-stimulated cardiac fibroblasts on Ly6C^hi^ MDMs (condition 3). Since there were very few Ly6C^lo^ MDMs in the co-culture with IL-17A-stimulated cardiac fibroblasts, this condition was not included for this analysis. We performed microarray-based transcriptomic profiling of RNA isolated from FACS-sorted macrophages derived from the three conditions in triplicate (see the gating strategy in [Figure S6A](#SD1){ref-type="supplementary-material"}). Gene expression profiles of the three MDM subsets were evaluated by principal-component analysis (PCA) and hierarchical clustering analysis ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Both analyses demonstrated distinct gene expression profiles for the three MDM subsets, suggesting that both the microenvironment and monocyte intrinsic properties are determining factors. Differential gene expression analysis showed that consistent with both PCA and hierarchical clustering analysis, Ly6C^lo^ MDMs versus Ly6C^hi^ MDMs from IL-17A-treated cardiac fibroblast culture had the greatest number of differentially expressed genes (n = 1,057). Whereas Ly6C^lo^ MDMs versus Ly6C^hi^ MDMs from non-treated cardiac fibroblasts culture had the lowest number of differentially expressed genes (n = 644) ([Figure S6B](#SD1){ref-type="supplementary-material"}). We found that IL-17A signaling through cardiac fibroblasts significantly upregulated genes encoding inflammatory chemokines, cytokines, growth factors, *Il6/Stat3*, and the nuclear factor κB (NFκB) pathway in Ly6C^hi^ MDMs ([Figures 6C](#F6){ref-type="fig"}--[6E](#F6){ref-type="fig"}). Moreover, IL-17A trans-signaling through cardiac fibroblasts upregulated genes in Ly6C^hi^ MDMs known to promote tissue fibrosis such as *Osm*, as well as genes related to extracellular matrix degradation including Mmp9 and Timp1 ([Figure 6F](#F6){ref-type="fig"}). In contrast, Ly6C^lo^ MDMs uniquely upregulated genes associated with class II antigen processing, including *Cd74* and *H2-Ab1* ([Figure 6D](#F6){ref-type="fig"}). Flow cytometric analysis showed that *in vitro* Ly6C^lo^ MDMs indeed expressed MHCII, strongly suggesting their antigen presentation capabilities ([Figure 6G](#F6){ref-type="fig"}). Ly6C^lo^ MDMs expressed a significantly higher level of MHCII than Ly6C^hi^ MDMs after being injected intracardially into EAM IL17Ra^−/−^ recipients ([Figure S6C](#SD1){ref-type="supplementary-material"}). Furthermore, MHCII^+^Ly6C^lo^ MDMs contribute to the increased proportion of MHCII^+^ macrophage in IL17Ra^−/−^ mice during the resolution phase of EAM at day 28 ([Figure 6H](#F6){ref-type="fig"}). We also validated that Ly6C^lo^ MDMs do not carry a dendritic cell signature ([Figure S6D](#SD1){ref-type="supplementary-material"}). IL-17A signaling through cardiac fibroblasts significantly upregulated many genes encoding both M1 and M2 markers in the Ly6C^hi^ MDMs, highlighting that the classic M1 and M2 paradigm cannot simply characterize macrophage activation complexity during disease states ([Figure S6E](#SD1){ref-type="supplementary-material"}) ([@R58]; [@R68]). We conclude that IL-17A trans-signaling through cardiac fibroblasts promotes pro-inflammatory and pro-tissue remodeling characteristics in Ly6C^hi^ MDMs. Interestingly, Ly6C^lo^ MDMs upregulate genes associated with antigen presentation and have elevated surface expression of MHCII both *in vitro* and *in vivo*. Our findings suggest that Ly6C^hi^ and Ly6C^lo^ MDMs represent distinct subsets that have unique roles and functions in the inflamed heart.

IL-17A Trans-Signaling through Cardiac Fibroblasts Downregulates MerTK Expression on Monocytes and MDMs {#S9}
-------------------------------------------------------------------------------------------------------

The clearance of apoptotic cells during inflammation resolution is critical for proper wound repair and tissue remodeling. The myeloid-epithelial-reproductive receptor tyrosine kinase (MerTK) is a major apoptotic cell receptor on macrophages, known to play a role in the clearance of dying cells, a process called efferocytosis ([@R80]; [@R97]). Efferocytosis is also known to induce an anti-inflammatory phenotype in macrophages and diminish proinflammatory cytokine release ([@R12]; [@R16]; [@R37]). EM results showed engulfed apoptotic cells or large cell debris inside Ly6C^hi^ MDMs ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). Their phagocytic index was significantly elevated compared to the Ly6C^lo^ MDMs derived from the co-culture ([Figure 7C](#F7){ref-type="fig"}). This indicates that Ly6C^hi^ MDMs are professional phagocytes. Consistent with our finding that IL-17A modulates the replenishment of the tissue macrophage pool with circulating monocytes, we observed an increase in the percentage of macrophages in IL-17Ra^−/−^ EAM hearts compared to WT EAM hearts ([Figure 7D](#F7){ref-type="fig"}; see the gating strategy in [Figure S7A](#SD1){ref-type="supplementary-material"}). In general, macrophages express considerably higher levels of MerTK than monocytes in the hearts ([Figure S7B](#SD1){ref-type="supplementary-material"}). We found that both monocytes and macrophages express higher levels of MerTK in IL17Ra^−/−^ hearts compared to WT ([Figures 7E](#F7){ref-type="fig"} and [7F](#F7){ref-type="fig"}). This suggests that IL-17A plays a role in downregulating MerTK expression on monocytes and macrophages. Furthermore, we found significantly less soluble Mer (sMer) present in IL17Ra^−/−^ mice sera than WT animals, indicating that IL-17A might influence the rate at which MerTK is proteolytically cleaved from the surface of the cell ([Figure 7G](#F7){ref-type="fig"}). In order to confirm that IL-17A signaling through cardiac fibroblasts was responsible for modulation of MerTK, we assessed MerTK expression *in vitro*. We confirmed that *in vitro* MerTK was predominantly expressed by Ly6C^hi^ but not Ly6C^lo^ monocytes and MDMs ([Figure 7H](#F7){ref-type="fig"}). Moreover, IL-17A signaling through cardiac fibroblasts resulted in a significant downregulation of MerTK expression on Ly6C^hi^ monocytes and MDMs ([Figure 7H](#F7){ref-type="fig"}). In addition, we observed that sMer was significantly elevated in the co-culture supernatants when IL-17A signaling was present ([Figure 7I](#F7){ref-type="fig"}). Our findings suggest that IL-17A-stimulated cardiac fibroblasts can suppress macrophages' phagocytic function by promoting MerTK cleavage, resulting in reduced surface MerTK expression. Our results also suggest that Ly6C^hi^ MDMs in WT EAM hearts have compromised phagocytic activities during heart inflammation. We retroorbitally injected fluorescein isothiocyanate (FITC)-conjugated latex beads in both IL17Ra^−/−^ and WT EAM mice. We found significantly more FITC^+^ macrophages in the hearts of IL17Ra^−/−^ compared to WT, indicating enhanced phagocytic activity in an IL-17A-signaling-deficient environment ([Figures 7J](#F7){ref-type="fig"} and [7K](#F7){ref-type="fig"}). Human myocarditis patients were reported to have high serum IL-17A, as well as an abundant presence of Th17 cells in their hearts and blood ([@R67]). Indeed, we found higher frequencies of IL-17A expressing infiltrating leukocytes in the hearts of myocarditis patients compared to patients with ischemic cardiomyopathy ([Figures S7C](#SD1){ref-type="supplementary-material"} and [S7D](#SD1){ref-type="supplementary-material"}; [Tables S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}). We therefore hypothesized that myocarditis patients could have lower MerTK expression in their cardiac myeloid population. In a cohort of HF patients, we found a significant reduction in myeloid MerTK expression in patients with myocarditis as compared to those with ischemic HF, similar to our finding in a murine model ([Figure 7L](#F7){ref-type="fig"}; [Tables S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}). In conclusion, IL-17A signals through cardiac fibroblasts to promote MerTK cleavage on Ly6C^hi^ MDMs, thus compromising the processes of efferocytosis. With reduced phagocytic ability as a result of surface MerTK modulation, we predict that macrophages are less efficient in clearing apoptotic cells efficiently and more likely to exhibit a proinflammatory phenotype, which in turn could promote irreversible cardiac remodeling and fibrosis.

DISCUSSION {#S10}
==========

Monocytes and macrophages are key effector cells in the injured myocardium during human myocarditis and EAM ([@R10]; [@R87]). Although both Ly6C^hi^ and Ly6C^lo^ monocytes infiltrate the myocardium during EAM, we found that an excessive accumulation of Ly6C^hi^ rather than Ly6C^lo^ monocytes in the heart leads to adverse cardiac remodeling and the development of DCM ([@R91]). However, it was unknown whether both infiltrating Ly6C^hi^ and Ly6C^lo^ monocytes contribute to the adverse cardiac tissue remodeling during development of EAM. Moreover, the role of the local pro-inflammatory cardiac microenvironment in influencing Ly6C^hi^ and Ly6C^lo^ monocyte fate and function was not well understood. We used three fate-mapping strategies to evaluate the phenotypic and functional changes of monocytes in the heart during myocarditis: parabiosis, adoptive transfer of monocytes, and an *in vitro* co-culture system.

Under steady state, adult cardiac tissue macrophages in mice are of mixed embryonic and hematopoietic origins ([@R26]; [@R36]; [@R45]; [@R79]; [@R82]). In cases of aging or perturbed homeostasis, a greater proportion of embryonic-derived macrophages are replaced by infiltrating monocytes, changing the landscape of macrophage dynamics in the heart. ([@R26]; [@R38]; [@R65]). Our parabiosis fate-mapping results reveal that monocytes extravasate into hearts during EAM and readily differentiate into macrophages, which contributes to the increase in the cardiac macrophage number during EAM. It was previously reported that cardiac CCR2^−^ macrophages, including MHCII^+^ and MHCII^−^ populations, are largely embryonically derived, whereas cardiac CCR2^+^ macrophages represent a hematopoietically derived lineage at steady state ([@R26]; [@R54]). Embryonically derived macrophages are shown to have regenerative and reparative properties ([@R7]; [@R54]), whereas CCR2^+^ macrophages are thought to initiate inflammation and contribute to adverse cardiac remodeling ([@R8]; [@R56]). We report here that infiltrating monocytes predominantly contribute to the CCR2^+^MHCII^+^ macrophage compartment. Albeit to a lesser extent, they are also able to differentiate into CCR2^−^MHCII^+^ macrophages, with very few becoming CCR2^−^MHCII^−^ macrophages in the chronically inflamed heart.

Ly6C^hi^ monocytes are known to replenish the macrophage pool during cardiac injury; however, the contribution of Ly6C^lo^ monocytes to the cardiac macrophage pool has not been previously described ([@R13]; [@R25]; [@R55]; [@R77]; [@R26]; [@R38]; [@R41]; [@R69]). Here, we show that both Ly6C^hi^ and Ly6C^lo^ monocytes have the capability to differentiate into macrophages, a process driven by direct contact with cardiac fibroblasts. Previously, we demonstrated that IL-17A can stimulate cardiac fibroblasts to produce significant amounts of GM-CSF ([@R91]). Evidence from EAM, Kawasaki syndrome, and the mouse model of MI show that cardiac fibroblasts are potent producers of GM-CSF ([@R4]; [@R18]; [@R84]; [@R91]). An accumulating body of literature indicates that GM-CSF plays a key role in signaling myelopoiesis in response to tissue injury. GM-CSF also induces a pathogenic transcriptional signature in pro-inflammatory monocytes propelling the inflammatory cascade, resulting in further tissue damage ([@R4]; [@R21]; [@R91]). Here, we show a profound inhibitory role of IL-17A as it works in trans through cardiac fibroblastderived GM-CSF on Ly6C^lo^ monocyte-to-macrophage differentiation *in vitro*. Other studies have implemented Ly6C^lo^ latex bead labeling methods to track Ly6C^lo^ monocytes *in vivo* ([@R72]; [@R86]). However, due to the inadequate labeling efficiency in the EAM model, we were unable to distinguish and quantify Ly6C^lo^ MDMs in EAM hearts using this method (data not shown). Alternatively, we used both intracardial and retro-orbital adoptive transfer methods and confirmed *in vivo* the inhibitory effect of IL-17A signaling on Ly6C^lo^ monocyte-to-macrophage differentiation. We hypothesize that these Ly6C^lo^ MDMs have distinct functions in myocarditis compared to Ly6C^hi^ MDMs.

Gene expression profiling results substantiate that Ly6C^hi^ and Ly6C^lo^ MDMs represent distinct cell types, possibly driven partly by intrinsic properties. Recent studies have demonstrated that Ly6C^hi^ and Ly6C^lo^ monocytes are phenotypically heterogenous populations. Intrinsic properties such as transcription factors regulate Ly6C^hi^ and Ly6C^lo^ monocyte fate and function during steady state or tissue injury ([@R60]; [@R92]; [@R47]; [@R78]; [@R61]). However, we found that IL-17A signaling through cardiac fibroblasts accentuates a pro-inflammatory and pro-tissue remodeling gene profile in Ly6C^hi^ MDMs. These macrophages upregulate genes such as *Il6*, *Mmp9*, *Timp1*, and *Osm*, all of which have been implicated in cardiac dysfunction and maladaptive cardiac remodeling ([@R35]; [@R40]; [@R43]; [@R51]; [@R52]; [@R66]). Unexpectedly, we found that Ly6C^lo^ MDMs are enriched with genes associated with class II antigen processing. We confirm that Ly6C^lo^ MDMs express higher levels of MHCII than their Ly6C^hi^ counterparts *in vitro*. IL17Ra^−/−^ mice develop EAM similarly to their WT counterparts, but are protected from DCM, cardiac fibrosis, and dysfunction ([@R9]). *In vivo*, IL17Ra^−/−^ EAM hearts contain more MHCII^+^ macrophages than WT EAM controls during disease resolution, coinciding with DCM protection in IL17Ra^−/−^ mice. The anti-inflammatory and proangiogenic properties of Ly6C^lo^ monocytes were previously investigated, and their roles in the resolution of cardiac inflammation were frequently highlighted ([@R41]; [@R69]; [@R91]). This suggests that MHCII^+^Ly6C^lo^ MDMs might be beneficial in disease resolution and contribute to the protection of IL17Ra^−/−^ mice from DCM and HF. The functions of Ly6C^lo^ MDMs were placed under scrutiny recently. It has been implicated that they are the precursors for wound-healing macrophages in a soft tissue injury model ([@R70]). Paradoxically, they were also shown to give rise to inflammatory macrophages in an autoimmune arthritis model ([@R62]). We offer clues that Ly6C^lo^ MDMs are a non-inflammatory and non-tissue-remodeling population. The increased presence of these macrophages and an increased Ly6C^lo^-to-Ly6C^hi^ ratio in EAM myocardium correlate with DCM protection in IL17Ra^−/−^ mice ([@R91]). Although phagocytic activity of Ly6C^lo^ MDMs is unremarkable, their potential antigen presentation capability predicts their immune regulatory role in the heart. Whether MHCII^+^Ly6C^lo^ MDMs play a role in effector and/or memory T cell or regulatory T cell activation in the heart requires further examination. Recent evidence indicated that MHCII^+^ macrophages loaded with cardiac myosin peptide are not effective in stimulating the proliferation of autoreactive CD4^+^ T cells ([@R5]). However, the beneficial effects of macrophages and regulatory T cell interactions during inflammation resolution and tissue regeneration have been reported ([@R71]; [@R73]). Currently, it remains unfeasible to selectively deplete Ly6C^lo^ monocytes in mice. However, further experiments utilizing Nr4a1^−/−^, CX3CR1^−/−^, or S1PR5^−/−^ mice with reduced Ly6C^lo^ monocytes can help to better assess the specific functional role of Ly6C^lo^ monocytes-derived macrophage in the context of myocarditis ([@R22]; [@R34]; [@R53]).

Macrophage function can be shaped by both progenitor origin and tissue microenvironment ([@R2]; [@R54]). We tested the hypothesis that upon IL-17A stimulation, cardiac fibroblasts play a role in modulating macrophage function. Recent data directly link the level of efferocytosis receptors on monocytes and macrophages to phagocytosis-dependent wound healing and restoration of organ function ([@R29]; [@R90]; [@R46]; [@R88]). Uncontrolled cellular necrosis and apoptosis during cardiac injury are integral components that contribute to adverse tissue healing and remodeling. Inefficient phagocytic clearance can also lead to exposure of self-antigens, which contribute further to autoimmune reactivity ([@R89]). One of these efferocytosis receptors, MerTK, has been shown to be upregulated on phagocytic cells during inflammation and plays an essential role in apoptotic cell recognition and clearance ([@R19]; [@R42]; [@R80]; [@R81]). Moreover, efferocytosis triggers a shift in macrophage activation, making them phenotypically less proinflammatory ([@R16]; [@R27]; [@R37]). Notably, our *in vivo* and *in vitro* results suggest that IL-17A signaling through cardiac fibroblasts leads to MerTK shedding and the release of sMer, which significantly reduces surface MerTK expression on Ly6C^hi^ monocytes and MDMs. Cardiomyocytes have been shown to induce shedding of macrophage MerTK to suppress phagocytosis ([@R95]). This highlights another mechanism by which IL-17A through cardiac fibroblasts can induce MerTK shedding and, in turn, contributes to cardiac pathology in autoimmune myocarditis. Moreover, we showed that myeloid MerTK was significantly lower in human myocarditis patients when compared to ischemic patients. These findings warrant future studies to determine whether sMer can be used as a biomarker in clinical settings to differentiate patients with myocarditis from those with other types of cardiac diseases.

Taken together, we underscore the fates of Ly6C^hi^ and Ly6C^lo^ monocyte subsets as a result of changes in the cardiac microenvironment. We demonstrate how the local cardiac milieu instructs cardiac fibroblasts to facilitate monocyte differentiation and proliferation as well as to regulate the phenotype and function of monocytes and MDMs. Monocytes are versatile immune cells playing a multi-faceted role in a wide range of inflammatory disorders ([@R6]; [@R63]; [@R64]; [@R69]; [@R70]; [@R75]). Our findings have broader implications for inflammatory diseases in the heart and other organs. We recently reported that IL-17A signaling to cardiac fibroblasts is associated with severe fibrosis and post-infarct death ([@R18]), which demonstrates a potential parallel concept that warrants future investigation. Ultimately, we anticipate that further studies of macrophage-cardiac fibroblast interactions will provide valuable insights into the development of targeted therapies that prevent deleterious inflammatory responses.

STAR⋆METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Daniela Ciháková (<cihakova@jhmi.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Patients {#S14}

Left ventricle apex endomyocardial biopsies were obtained from patients with end stage heart failure (AHA stage D) of various etiologies. These patients were undergoing either an implantation of Left Ventricular Assist Device (LVAD), or an orthotopic heart transplant after LVAD explant at the Texas Heart Institute. Details including patients' age and gender are summarized in [Table S1](#SD1){ref-type="supplementary-material"} -- [3](#SD1){ref-type="supplementary-material"}. Informed consent was obtained from human subjects and the study protocol was approved by the Committee for the Protection of Human Subjects (University of Texas Health Science Center at Houston. IRB \#HSC-MS-05--0074). Samples were properly preserved in cryovials embedded in liquid nitrogen (−190°C) and then kept at −80°C in the tissue bank at the Texas Heart Institute, Houston, TX as previously described ([@R76]). Aliquots of the samples were shipped frozen and processed in house. Reported diagnoses corresponded to clinical charts, based on standard histology (H&E), clinical presentation, hemodynamic parameters, and routine clinical biochemical and serology parameters. Patient's information of all samples was processed with random non-linked code relabeling in a database at the time of preservation. Furthermore, for each sample, a separate random non-linked code was assigned for the analysis process. Separately, one paraffin embedded, virus negative, acute giant cell myocarditis left ventricle transmural endomyocardial biopsy sample in [Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"} were provided by Dr. Karin Klingel. The sample was taken for routine diagnostic purposes to identify infectious agents in the myocardium as described before ([@R98]). Informed consent was obtained and the study was approved by local ethic committee (Project-No.253/2009BO2). Diagnosis of giant cell myocarditis was based on established criteria ([@R15]).

### Mice {#S15}

IL-17Ra^--/--^ mice on BALB/c background were provided by Amgen Inc. (Thousand Oaks, CA) and Dr. J. Kolls (Children's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA) ([@R91]; [@R94]). CByJ.SJL(B6)-*Ptprc*^a^/J (CD45.1) mice (006584) and WT BALB/cJ (000651) mice were purchased from The Jackson Laboratory. IL-17Ra^--/--^ mice were crossed to CByJ.SJL(B6)-*Ptprc*^a^/J (CD45.1) mice and bred to homozygosity at both loci. All mice were housed and maintained in the Johns Hopkins University School of Medicine specific pathogen-free vivarium. 6 -- 10 weeks old healthy naive male mice were randomly selected as the subjects of all of our studies. All experiments involving animals were in compliance with the Animal Welfare Act and strictly followed the Guide for the Care and Use of Laboratory Animals. The Animal Care and Use Committee of The Johns Hopkins University has approved all procedures and protocols used in this study.

### Primary Adult Cardiac Fibroblasts Isolation and Culture {#S16}

50U heparin was injected *i.p*. into 6 -- 10-week-old male BALB/cJ naive mice prior to sacrifice. Hearts were cannulated through the aorta and perfused for 3 minutes with 37°C perfusion buffer at 4 mL/minute: 7.03 g/L NaCl, 1.1 g/L KCl, 0.082 g/L KH~2~PO~4~, 0.085 g/L Na~2~HPO~4~, 0.144 g/L MgSO~4~, 2.38 g/L HEPES, 0.39 g/L NaHCO~3~, 1 g/L glucose, 3.74 g/L Taurine, 1 g/L 2,3-Butanedione monoxime (all Sigma), and for 8 min with Collagenase II and Protease XIV (Worthington) and 0.03M CaCl~2~. Hearts were cut into small pieces and cells separated by gently pipetting for 3 minutes or until no large tissue pieces were observed. Cells were filtered through a 100 mm filter and washed in DMEM (GIBCO). Cells were plated in DMEM with 20% FBS (GE Healthcare Life Sciences), nonessential amino acids (Sigma), Penicillin/Streptomycin, 2 mM L-Glutamine, and 25mM HEPES (all Quality Biological). Cells were incubated in a humidified 5% CO~2~ incubator at 37°C from here on. Non-adherent cells were washed away after 1 hour. Fibroblasts from second passage were used in experiments. The purity of cardiac fibroblast cultures was confirmed by qPCR and flow cytometry. Cells and supernatants were harvested at the indicated time points after addition of recombinant mouse cytokine IL-17A at 50 ng/mL or recombinant mouse GM-CSF at 50ng/mL (Peprotech). LEAF™ Purified anti-GM-CSF at 50μg/mL was used (MP1--22E9, BioLegend). Monocytes and fibroblasts separation in the co-culture was achieved by 0.4 μM transwell inserts (Corning).

METHOD DETAILS {#S17}
--------------

### Parabiosis Surgery {#S18}

Pairs of mice were anesthetized by isoflurane inhalation, 4.0--5.0% v/v induction (Baxter). Fur was removed thoroughly from the entire flank region using clippers. Anesthesia in surgical pairs was maintained with intramuscular injections of ketamine (80 mg/kg) and xylazine (16 mg/kg). The mice were laid supine and the site was disinfected with betadine followed by 70% EtOH. We administered buprenorphine (0.1 mg/kg) intraperitoneally for the initial analgesia, and at 12 hours postoperatively. Longitudinal incisions were made through the skin starting from the elbow joint and extended down to the knee joint. Non-absorbable 4--0 interrupted sutures were placed around the knee and elbow joints. Pairs where attached from the elbow joints first. To increase skin anastomosis, we used a continuous 5--0 absorbable vicryl sutures through the muscular layer and connect the pairs further, before attaching the knee joints. Surgical stapler was used to connect the skins of the pairs. Baytril was used upon completion of the procedure. Animals were provided with moistened chow and gel food diet supplement every other day until sacrifice at 19 to 20 days after parabiosis.

### EAM Induction {#S19}

To induce EAM, we injected mice with 125 μg myosin heavy chain α peptide MyHCα~614--629~ (Ac-SLKLMATLFSTYASAD; Genscript) ([@R74]) emulsified in CFA (Sigma-Aldrich) supplemented with 5mg/mL heat-killed *Mycobacterium tuberculosis* strain H37Ra (Difco) on days 0 and 7. On the first day of immunization, mice also received a dose of 500 ng pertussis toxins intraperitoneally (List Biological Laboratories) ([@R20]).

### EAM Histopathology Assessments {#S20}

Myocarditis severity was evaluated by histology on days 21. Heart tissues were fixed in SafeFix solution (Thermo Fisher Scientific), embedded and cut into 5 μm serial sections. Sections were stained with H&E and ventricular inflammation was scored via a microscope by two independent blinded investigators and averaged using the following criteria for hematopoietic infiltrates: grade 0, no inflammation; grade 1, \< 10% of the heart section is involved; grade 2, 10%--30%; grade 3, 30%--50%; grade 4, 50%--90%; grade 5, \> 90% ([@R20]).

### Isolation of Splenic Ly6C^hi^ and Ly6C^lo^ Monocytes {#S21}

Spleens from WT or IL-17Ra^--/--^ BALB/c mice on day 14 of EAM were dissected and mechanically disrupted. Cells were filtered through 40 mm cell strainers and washed. Histopaque 1119 and 1077 (Sigma) were used to isolate mononuclear cells. Anti-Ly6G MicroBead kit (Miltenyi Biotech) was used to deplete Ly6G^+^ cells, and CD11b MicroBead kit (Miltenyi Biotech) was used to positively enrich CD11b^+^ cells. Cells were sorted on an AriaIIu cell sorter. Sorted cells from IL-17Ra^--/--^ BALB/c mice spleens were used for *in vitro* co-culture with primary cardiac fibroblasts, major outcomes were validated with sorted cells from WT BALB/c mice spleens co-cultured with cardiac fibroblasts. Sorted cells from WT BALB/c mice spleens were used in adoptive transfer experiments (see below).

### Cell Staining and Light Microscopy {#S22}

Modified Giemsa staining was achieved by using Differential Quik Stain Kit, following the manufacturer's instructions (Polysciences). Cell staining images were acquired on Olympus BX43 microscope with a camera (DP72) using cellSens Standard software (version 1.4.1; Olympus).

### IncuCyte ZOOM Imaging {#S23}

Once the monocyte-fibroblast co-cultures were established, the plates were placed into the IncuCyte ZOOM™ (Essen Bioscience) apparatus and images of cells were recorded with 20 × magnification undisturbed every 1 hour for a total duration of 160 hours. Cardiac fibroblasts alone were used as controls and triplicated wells were included in all data acquisitions.

### Transmission Electron Microscopy {#S24}

Co-cultured cells were washed with 1 × PBS and fixed in 2.5% glutaraldehyde dissolved in 0.1 M Na cacodylate. Samples were then processed by the Johns Hopkins Microscope Facility ([@R24]) before examination using the Philips CM120 transmission electron microscope. Images were captured using Advanced Microscopy Techniques V602 software. The phagocytic index was calculated according to the following formula: phagocytic index = (total number of engulfed cells/total number of counted macrophages) × (number of macrophages containing engulfed cells/total number of counted macrophages) × 100. Approximately 60 total macrophages derived from each monocyte subset were counted, numbers were acquired from two separate assessments.

### Immunofluorescence Microscopy {#S25}

Human paraffin-embedded giant cell myocarditis biopsy sample slides were processed using xylene and rehydrated with decreasing concentration of ethyl alcohol and rinsed with distilled water. After blocking with 1% BSA and 0.1% tween-20 in 1 × PBS, tissues were incubated with anti-CD14-biotin sheep antibodies (R & D systems) and anti-CD68 mouse antibodies (Abcam). We then used NL-637 Streptavidin and donkey NL-557 anti-mouse IgG (R & D systems) as secondary antibodies diluted in 0.05% Evans Blue for counterstaining. DAPI was used for staining nuclei. Finally, Sudan Black was used to suppress auto-fluorescence as a result of tissue fixation and paraffin treatment. Images were acquired using Zeiss Axio Imager.A2 microscope with AxioCam MRm at 20 × magnification. We used AxioVision Rel. 4.8 software to acquire images and Adobe Photoshop CC to process images.

### Intracardiac Injection {#S26}

WT or IL-17Ra^--/--^ BALB/c mice on day 21 of EAM were depilated and anesthetized with 3.5% isoflurane (Baxter). The mice were subsequently endotracheally intubated, 100% oxygen and 2% isoflurane were provided to the animals throughout the operation by mechanical ventilation (Model 845, Harvard Apparatus). Pre-operational analgesics (0.05 mg/kg Buprenorphine, Reckitt Benckiser) and paralytics (1 mg/kg Succinylcholine, Henry Schein) were administered prior to operation. Mice were subjected to a thoracotomy, typically around the 4th or 5th intercostal space to expose the heart ventricles. Roughly 1.5 -- 2 × 10^5^ cells were injected with a 29G 29G ½ insulin syringe (BD) into 2 -- 3 ventricular locations. Mice were placed under the heat lamp to recover post-surgery, post-operational analgesics (0.05 mg/kg Buprenorphine, Reckitt Benckiser) were administered. Mice were sacrifice at 40 hours or at 160 hours post-surgery to assess cell transfer outcomes.

### Retro-Orbital Injection of Monocytes {#S27}

WT or IL-17Ra^--/--^ BALB/c mice on day 21 of EAM were depilated and anesthetized with 100% oxygen and 3.5% isoflurane (Baxter). Mice were subjected to an injection into the ophthalmic venous sinus. Roughly 4 -- 5 × 10^5^ FACS sorted monocytes were injected with a 29G ½ insulin syringe (BD).

### Retro-Orbital Injection of Liposomes and Latex Beads {#S28}

We administered a single treatment of 10 μl Clodrosome (clodronate loaded liposomes; Encapsula Nano Sciences) per gram of animal weight seventeen hours prior to latex microsphere labeling to better visualize FITC^+^ macrophages *in vivo*. 0.5-μm FITC-conjugated (yellow gold) plain microspheres (2.5% solids \[wt/vol\]; Polysciences, Inc.) were diluted 1:25 in 1XPBS. We administered 250 μl of the diluted latex beads to examine macrophage phagocytic activity *in vivo*. Hearts were harvested 24 hours post bead administration.

### Quantitative Reverse Transcription PCR {#S29}

Cell mRNAs were extracted in TRIzol (Invitrogen), and reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Target cDNAs were amplified with Power SYBR Green PCR Master Mix (Bio-Rad) and real time cycle thresholds were detected via MyiQ2 themocycler running on an iQ5 software (Bio-Rad). Target genes fold induction were calculated using the 2^−ΔΔCt^ method by normalizing cycle thresholds to the *Hprt* housekeeping gene and medium controls ([@R57]). Verified *Ccl2* primer sequences were acquired from the PrimerBank (Harvard Medical School, Massachusetts General Hospital and The Center for Computational and Integrative Biology), and commercially synthesized (Integrated DNA Technologies). *Ccl2* forward primer sequence (5′ to 3′): TTAAAAACCTGGATCGGAACCAA, and reverse primer sequence (5′ to 3′): GCATTAGCTTCAGATTTACGGGT.

### Flow Cytometry Analysis and Barnes-Hut Stochastic Neighbor Embedding Analysis {#S30}

Hearts of naive or EAM mice were perfused through the ventricles with 1 × PBS for 3 minutes. GentleMACS C Tubes were used to mechanically disassociate the tissue according to manufacturer's instructions (Miltenyi Biotech). We used 3000 U Collagenase II and 300 U DNase I (Worthington) dissolved in 5mL HBSS to digest tissue and obtain single cell suspension. Splenocytes, blood, and BM cells (femurs and tibias) were isolated by mechanical disruption, followed by red blood cell lysis using ACK buffer (ThermoFisher). Heart samples were filtered through 40 μm filters, whereas the other tissues were filtered through 70 μm filters. Single-cell suspensions were stained with LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (ThermoFisher), washed, FcγRII/III blocked with a-CD16/CD32, and stained with fluorochrome-conjugated antibodies (eBioscience, BioLegend, BD PharMingen). Alternatively, we used APC Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend) instead of LIVE/DEAD. CellTrace™ CFSE Kit was used to track cell proliferation both *in vivo* and *in vitro* (ThermoFisher). Samples were acquired on a BD LSRII or LSRFortessa 4-laser cytometers running FACSDiva 6.0 (BD Immunocytometry) and analyzed using FlowJo 10.4 software. We ran an interactive visualization tool called cyt in MATLAB to analyze high-dimensional flow cytometry data ([@R11]; [@R1]). bh-SNE is an unsupervised non-linear dimensionality reduction embedding technique ([@R1]).

### Microarray {#S31}

Ly6C^hi^ and Ly6C^lo^ *in vitro* co-culture derived macrophages in triplicate were FACS sorted and cells were lysed using RLT buffer (QIAGEN). RNA was extracted using RNeasy micro kit. RNA samples were labeled using Thermal Fisher 3′ IVT Pico Reagent kit (Affymetrix) according to manufacturer's guidelines and probed using the Affymetrix Mouse Clariom S Array. RNA concentration and integrity were determined with Agilent Bioanalyzer Pico Chip.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S32}
---------------------------------------

### Statistical Analysis {#S33}

GraphPad Prism 7 software was used for statistical analysis. Statistical analysis details are described in the figure legends. To determine if datasets show a normal distribution, either the D'Agostino-Pearson or the Shapiro-Wilk normality test was used. P values were considered statistically significant at p \< 0.05. All data were presented as mean ± SD.

DATA AND CODE AVAILABILITY {#S34}
--------------------------

### Microarray Gene Expression Analysis {#S35}

Raw data generated from Clariom S Arrays were processed using Affymetrix Expression Console Software. CEL files containing feature intensity values were converted into summarized expression values by Partek Genomic Suite Software including background adjustment, quantile normalization and summarization across all chips. All samples passed QC thresholds for hybridization, labeling and the expression of spiked in controls. The variances, both between and within groups, in log2 transformed expression values were analyzed by one-way ANOVA. PCA graph was generated using Partek Genomic Suite Software, heatmaps were generated using TIBCO Spotfire Software. The complete normalized dataset is available on GEO: GSE118861.
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![Infiltrating Monocytes Contribute to Three Subsets of Macrophages during Myocarditis\
(A) Schematics of parabiosis mice.\
(B) Representative images of H&E-stained heart sections of the median CD45.1 (day 21 EAM) and CD45.2 (non-EAM) mice parabionts. Scale bars: 100 μm.\
(C) Comparison of total grafted CD11b^+^Ly6G^−^myeloid cell counts between parabionts.\
(D) Comparison of total cardiac macrophage counts between parabionts.\
(E) Flow cytometry plots showing (top left) percentage of CD45.2^+^CD11b^+^Ly6G^−^Lineage (CD3e, B220, NKp46, CD90.2, and Ter119)^−^ grafted cells infiltrating the CD45.1 EAM hearts; (top middle) percentage of grafted cells in the hearts that differentiated into macrophages or remained as monocytes; (top right) percentage of grafted MDM subsets; (bottom left) percentage of CD45.1^+^CD11b^+^Ly6G^−^Lineage grafted cells infiltrating the CD45.2 non-EAM hearts; (bottom middle) percentage of grafted cells in the hearts that differentiated into macrophages or remained as monocytes; and (bottom right) percentage of grafted MDM subsets.\
(F) Percentages of grafted MDMs out of total number of grafted CD11b^+^Ly6G^−^Lineage^−^ myeloid cells.\
(G) Percentages of grafted Ly6C^hi^ and Ly6C^lo^ cells out of total number of grafted F4/80^−^CD64^+^ monocytes.\
(H) Comparison of grafted MDM subsets defined by CCR2 and MHCII expressions between parabionts. Data are representative of two independent experiments with biological triplicates. n = 3.\
(C, D, F, G) Groups were compared using Student's t test. \*p \< 0.05. All data were presented as mean ± SD.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1533545-f0002){#F1}

![Cardiac Fibroblasts Facilitate Ly6C^hi^ and Ly6C^lo^ Monocyte-to-Macrophage Differentiation\
(A) Schematics of the monocytes and cardiac fibroblasts co-culture system. Cardiac fibroblasts were harvested from WT naive mice, whereas monocytes weresorted from EAM IL-17Ra^−/−^ mice.\
(B) Flow cytometric analysis showing differentiation of viable Ly6C^hi^ and Ly6C^lo^ MDMs expressing F4/80^hi^CD64^+^ at 40 h.\
(C) Frequency of macrophage differentiation at 40 h.\
(D) Differentiation of viable Ly6C^hi^ and Ly6C^lo^ monocytes into MDMs at 160 h.\
(E) Frequency of macrophage differentiation at 160 h.\
(F) Giemsa staining of monocytes morphologies before culture and after 160 h co-culture with cardiac fibroblasts. Scale bars: (black) 8 μm.\
(G and H) IncuCyte results showing CFSE^+^Ly6C^hi^ (G) and CFSE^+^Ly6C^lo^ (H) monocytes are in close contact with cardiac fibroblasts. Scale bars: (white) 50 μm.\
(I--L) Representative EM images taken at 160 h of co-culture showing individual (I) Ly6C^hi^ and (J) Ly6C^lo^ MDMs and (K) Ly6C^hi^ and (L) Ly6C^lo^ MDMs interacting with cardiac fibroblasts. Scale bars: (white) 2 μm; (black) 2 μm.\
(A--F) Data are representative of five independent experiments with technical triplicates. (C and E) n = 3. Groups were compared using one-way ANOVA followed by Tukey test. \*\*\*\*p \< 0.0001. All data were presented as mean ± SD.\
See also [Figure S2](#SD1){ref-type="supplementary-material"} and [Videos S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}.](nihms-1533545-f0003){#F2}

![Inflammatory Monocytes Are the Main Precursors for MDMs during Myocarditis in Both Mice and Humans\
(A) Schematics of intracardiac injection of Ly6C^hi^ or Ly6C^lo^ CD45.2^+^ splenic monocytes into the hearts of CD45.1 day 21 EAM WT recipient mice.\
(B and C) Gating of concatenated Ly6C^hi^ (B) and Ly6C^lo^ (C) donor cells from the total viable CD115^+^CD11b^+^ population.\
(D) Percentages of injected Ly6C^hi^ or Ly6C^lo^ monocytes differentiated into macrophages.\
(E and F) Flow cytometric analysis of the frequencies of Ly6C^hi^ (E) and Ly6C^lo^ (F) MDMs out of a viable CD45.2^+^CD115^+^CD11b^+^ population.\
(G and H) F4/80 and CD64 expression intensities of Ly6C^hi^ (G) and Ly6C^lo^ (H) MDMs using a bh-SNE-dimensional reduction algorithm.\
(D) Data are representative of three independent experiments. n = 3--4. Groups were compared using Student's t test. \*\*p \< 0.01. All data were presented as mean ± SD.\
See also [Figure S3](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1533545-f0004){#F3}

![IL-17A Signaling through Cardiac Fibroblasts Inhibits Ly6C^lo^ Monocyte-to-Macrophage Differentiation and Ly6C^lo^ Proliferation\
Naive WT cardiac fibroblasts were co-cultured with monocytes sorted from EAM IL-17Ra^−/−^ mice. All co-cultured cells were assessed using flow cytometry at 160 h.\
(A) Gating of concatenated Ly6C^hi^ and Ly6C^lo^ MDMs out of viable CD45^+^CD11b^+^.\
(B) Histograms of mean CFSE fluorescent intensity (MFI) of viable Ly6C^hi^ cells and Ly6C^lo^ cells after co-culturing with either cardiac fibroblasts or IL-17A-treated cardiac fibroblasts.\
(C and D) Percentages of Ly6C^hi^ (C) and Ly6C^lo^ (D) MDMs when co-cultured with cardiac fibroblasts only, IL-17A-stimulated cardiac fibroblasts, recombinant GM-CSF supplemented cardiac fibroblasts, and IL-17A-stimulated cardiac fibroblasts treated with anti-GM-CSF, respectively.\
(E and F) Histograms of CFSE MFI showing viable Ly6C^hi^ MDMs (E) and Ly6C^lo^ monocytes (F) in conditions described in (C) and (D).\
(C and D) Data are representative of three independent experiments with technical triplicates. n = 3. Groups were compared using one-way ANOVA followed by Dunnett test. \*p \< 0.05; \*\*\*\*p \< 0.0001. All data were presented as mean ± SD.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1533545-f0005){#F4}

![The Absence of IL-17A Signaling Enables Ly6C^lo^ Monocyte-to-Macrophage Differentiation *In vivo*\
(A) Schematics of intracardiac injection of CD45.2^+^Ly6C^hi^ or CD45.2^+^Ly6C^lo^ monocytes into CD45.1 day 21 EAM IL-17Ra^−/−^ recipient mice.\
(B and C) Gating of concatenated Ly6C^hi^ (B) and Ly6C^lo^ (C) donor cells from the total viable CD115^+^CD11b^+^ population.\
(D) Percentages of injected Ly6C^hi^ or Ly6C^lo^ MDMs.\
(E and F) Frequencies of Ly6C^hi^ MDMs (E) and Ly6C^lo^ MDMs (F) out of the viable CD45.2^+^CD115^+^CD11b^+^ population.\
(G and H) F4/80 and CD64 expression intensities of Ly6C^hi^ (G) and Ly6C^lo^ (H) MDMs using bh-SNE-dimensional reduction algorithm.\
(I) Schematics of retro-orbital injection of CD45.1^+^Ly6C^lo^ monocytes into CD45.2 day 21 EAM WT or IL-17Ra^−/−^ recipient mice.\
(J) Gating of concatenated Ly6C^lo^ donor cells from the total viable CD115^+^CD11b^+^ population in WT and in IL-17Ra^−/−^ recipient ice.\
(K) CD45.1^+^ monocytes were gated based on no injection control CD45.2^+^ mice.\
(L) Percentages of CD45.1+ Ly6C^lo^ MDMs in the heart.\
(M) Frequencies of Ly6C^lo^ MDMs out of the viable CD45.1^+^CD115^+^CD11b^+^ population in WT and in IL-17Ra^−/−^ recipient mice. Data are representative of two independent experiments with biological triplicates.\
(D and L) n = 3. Groups were compared using Student's t test. \*p \< 0.05, \*\*p \< 0.01. All data were presented as mean ± SD.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1533545-f0006){#F5}

![Distinct Gene Expression Profiles in Ly6C^hi^ and Ly6C^lo^ MDM Subsets Differentiated *In vitro* in the Presence of Untreated or IL-17A-Treated Cardiac Fibroblasts\
(A) PCA analysis of microarray experiments. The principal components and their fraction of overall variability of the data (%) are shown on the x, y, and z axes.\
(B) Supervised hierarchical clustering highlighting differential gene expression profiles among three groups of *in vitro* MDMs, using a threshold of 2-fold change and p value \< 0.05. Sample number scheme is identical to the legend in all heatmaps below.\
(C--F) Heatmaps showing relative fold changes in (C) genes associated with cytokines and growth factors, (D) NFκB pathway and antigen presentation, (E) chemokines and immune modulating activities, and (F) collagen production and matrix remodeling.\
(G) Gating of MHCII^+^CD64^+^ macrophages derived from monocyte-fibroblast co-culture. Frequencies of MHCII^+^ subset out of total *in vitro* co-culture MDMs were assessed by flow cytometry.\
(H) Frequencies of MHCII^+^ out of F4/80^hi^CD64^+^ macrophages were assessed by flow cytometry of the hearts of day 28 EAM mice.\
(B--F) All genes displayed on the heatmaps have one-way ANOVA p value \< 0.05 among groups compared. Data are representative of three independent experiments with technical triplicates. (G) n = 3. (H) n = 8 -- 9. (G) Groups were compared using one-way ANOVA followed by Dunnett test. \*\*p \< 0.01. (H) Groups were compared using Student's t test. \*\*p \< 0.01. All data were presented as mean ± SD.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1533545-f0007){#F6}

![IL-17A Trans-Signaling through Cardiac Fibroblasts Downregulates MerTK expression on Monocytes and MDMs\
(A and B) Representative EM images showing (A) apoptotic cells or apoptotic cellular debris internalized by Ly6C^hi^ MDMs (arrowheads) and (B) engulfed cellular debris were largely absent in Ly6C^lo^ MDMs. Scale bars: 2 μm.\
(C) Macrophage phagocytic index was calculated using the following formula: (number of engulfed apoptotic cells/total number of macrophages) × (number of macrophages with engulfed apoptotic cells/total number of macrophages) × 100.\
(D--G) Hearts from day 21 EAM mice.\
(D) Frequencies of F4/80^hi^CD64^+^ macrophages out of viable CD45^+^Ly6G^--^CD11b^+^ cells were assessed by flow cytometry.\
(E and F) MerTK MFI of F4/80^hi^CD64^+^ macrophages (E) and F4/80^--^CD64^+^ monocytes (F) in the hearts.\
(G) ELISA showing soluble Mer (sMer) in WT and IL-17Ra^−/−^ EAM mice sera.\
(H and I) Cardiac fibroblasts were harvested from WT naive mice, whereas monocytes were sorted from EAM IL-17Ra^−/−^ mice.\
(H) MerTK MFI of Ly6C^hi^ or Ly6C^lo^ monocytes and MDMs *in vitro* after 160 h post-co-culture with cardiac fibroblasts stimulated with or without IL-17A.\
(I) sMer detected in supernatants of the monocyte-fibroblast co-culture by ELISA.\
(J) Flow cytometric analysis of the frequencies of FITC^+^F4/80^hi^CD64^+^ macrophages in the myocardium of WT, IL-17Ra^−/−^, and non-treated controls.\
(K) Percentages of FITC^+^F4/80^hi^CD64^+^ macrophages out of viable CD45^+^Ly6G^--^CD11b^+^ cells.\
(L) MerTK MFI in patients with either myocarditis or ischemic cardiomyopathy.\
(D--G) Data are representative of five independent experiments. n = 8 -- 9. (H and I) Data are representative of three independent experiments with technical triplicates. n = 3. (J and K) Data are representative of two independent experiments. n = 3. (C--G, I, K, and L) Groups were compared using Student's t test. \*p \< 0.05; \*\*p \< 0.01. (H) Groups were compared using one-way ANOVA followed by Dunnett test. \*\*p \< 0.01; \*\*\*\*p \< 0.0001. All data were presented as mean ± SD.\
See also [Figure S7](#SD1){ref-type="supplementary-material"} and [Tables S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}.](nihms-1533545-f0008){#F7}

  REAGENT or RESOURCE                                                SOURCE                                                                                 IDENTIFIER
  ------------------------------------------------------------------ -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                                                
  BUV 395 Hamster anti-Mouse CD11c (clone HL3)                       BD Horizon                                                                             Cat\# 564080; RRID:AB_2738580
  BUV 395 Hamster IgG1, λ1 Isotype Control (clone G235--2356)        BD Horizon                                                                             Cat\# 564075
  BV 421 anti-Mouse CCr2 (clone SA203G11)                            BioLegend                                                                              Cat\# 150605; RRID:AB_2571913
  BV 605 anti-Mouse CD115 (clone AFS98)                              BioLegend                                                                              Cat\# 135517; RRID:AB_2562760
  PE anti-Mouse MerTK (Clone 2B10C42)                                BioLegend                                                                              Cat\# 151506; RRID:AB_2617037
  PE Rat IgG2a Isotype Control (Clone RTK2758)                       BioLegend                                                                              Cat\# 400508; RRID:AB_326530
  PerCP/Cy5.5 anti-Mouse/Human CD11b (clone M1/70)                   BioLegend                                                                              Cat\# 101228; RRID:AB_893232
  APC eflour 780 anti-Mouse Ly6C (clone HK1.4)                       Invitrogen                                                                             Cat\# 47--5932--82; RRID:AB_2573992
  PE Cy7 anti-Mouse F4/80 (clone BM8)                                BioLegend                                                                              Cat\# 123114; RRID:AB_893478
  PE Texas Red anti-Mouse CD45                                       Invitrogen                                                                             Cat\# MCD4517; RRID:AB_10392557
  PE anti-Mouse CD11c (clone N418)                                   BioLegend                                                                              Cat\# 117307; RRID:AB_313776
  PE Armenian Hamster IgG1 (clone HTK888)                            BioLegend                                                                              Cat\# 400907; RRID:AB_326593
  BV 711 anti-Mouse CD64 (clone X45--5/7.1)                          BioLegend                                                                              Cat\# 139311; RRID:AB_2563846
  BV785 anti-Mouse Ly6G (clone 1A8)                                  BioLegend                                                                              Cat\# 127645; RRID:AB_2566317
  FITC anti-Mouse Ly6G (clone 1A8)                                   BioLegend                                                                              Cat\# 127606; RRID:AB_1236494
  FITC anti-Mouse NKp46 (clone 29A1.4)                               BioLegend                                                                              Cat\# 137606; RRID:AB_2298210
  FITC anti-Mouse CD49b clone DX5                                    BioLegend                                                                              Cat\# 108906; RRID:AB_313413
  FITC anti-Mouse CD19 (clone 65)                                    BioLegend                                                                              Cat\# 115506; RRID:AB_313641
  FITC anti-Mouse TER119 (clone TER-119)                             BioLegend                                                                              Cat\# 116206; RRID:AB_313707
  FITC anti-Mouse CD3e (clone 145--2C11)                             BioLegend                                                                              Cat\# 100306; RRID:AB_312671
  FITC anti-Mouse TCRβ chain (Clone H57--597)                        BioLegend                                                                              Cat\# 109206; RRID:AB_313429
  FITC anti-Mouse CD11c (clone N418)                                 BioLegend                                                                              Cat\# 117306; RRID:AB_313775
  Alexa Flour 700 anti-Mouse I-A/I-E (clone M5/114.15.2)             BioLegend                                                                              Cat\# 107622; RRID:AB_493727
  BV 605 rat IgG2a, kappa Isotype control (Clone RTK2758)            BioLegend                                                                              Cat\# 400539; RRID:AB_11126979
  APC anti-mouse NK-46 (clone 29A1.4)                                BioLegend                                                                              Cat\# 137607; RRID:AB_10612749
  APC anti-mouse B220 (clone RA3--6B2)                               BioLegend                                                                              Cat\# 103211; RRID:AB_312996
  APC anti-mouse CD90.2 (clone 53--2.1)                              BioLegend                                                                              Cat\# 140311; RRID:AB_10645337
  APC anti-mouse CD3 (clone 17A2)                                    BioLegend                                                                              Cat\# 100236; RRID:AB_2561456
  APC anti-mouse CD19 (clone 65)                                     BioLegend                                                                              Cat\# 115512; RRID:AB_313647
  Pacific Blue anti-mouse F4/80                                      Invitrogen                                                                             Cat\# MF48028; RRID:AB_10373419
  PE Dazzle 594 CD45.1 (clone A20)                                   BioLegend                                                                              Cat\# 110748; RRID:AB_2564295
  APC CD45.1 (clone A20)                                             BioLegend                                                                              Cat\# 110714; RRID:AB_313503
  PE/Dazzle 594 anti-mouse CD45.2 (Clone 104)                        BioLegend                                                                              Cat\# 109845; RRID:AB_2564176
  APC anti- mouse CD45.2 (clone 104)                                 BioLegend                                                                              Cat\# 109813; RRID:AB_389210
  BV711 anti- mouse IgG1 Isotype control (clone MOPC-21)             BioLegend                                                                              Cat\# 400167; RRID:AB_11218607
  PE Cy7 Rat IgG2a Isotype control (clone RTK2758)                   BioLegend                                                                              Cat\# 400522; RRID:AB_326542
  PE anti- mouse CD135 (clone A2F10)                                 BioLegend                                                                              Cat\# 135305; RRID:AB_1877218
  PE Rat IgG2b Isotype control (clone eB149/10H5)                    eBioscience                                                                            Cat\# 12--4031--81; RRID:AB_470041
  Pacific Blue anti- mouse Ly6G (clone 1A8)                          BioLegend                                                                              Cat\# 127612; RRID:AB_2251161
  Pacific Blue anti-human/mouse CD11b (clone M1/70)                  BioLegend                                                                              Cat\# 101224; RRID:AB_755986
  BV421 anti-human/mouse CD11b (clone M1/70)                         BioLegend                                                                              Cat\# 101235; RRID:AB_10897942
  BUV 395 Rat anti-mouse CD117 (clone 2B8)                           BD Horizon                                                                             Cat\# 564011; RRID:AB_2738541
  BV650 anti-mouse Ly6G (clone 1A8)                                  Biolegend                                                                              Cat\# 127641; RRID:AB_2565881
  BV785 anti-mouse CD45.2 (clone 104)                                Biolegend                                                                              Cat\# 109839; RRID:AB_2562604
  Donkey NL-557 anti-mouse IgG                                       R&D Systems                                                                            Cat\# NL007; RRID:AB_663768
  Northern Lights 637 Streptavidin                                   R&D Systems                                                                            Cat\# NL998; RRID:AB_10175723
  Goat anti-Rabbit IgG HNL                                           Abcam                                                                                  Cat\# AB150077; RRID:AB_2630356
  Human CD14 Biotinylated Antibody                                   R&D Systems                                                                            Cat\# BAF383; RRID:AB_356435
  Recombinant CD16 antibody                                          Abcam                                                                                  Cat\# AB109223; RRID:AB_10863447
  Anti-CD68 antibody                                                 Abcam                                                                                  Cat\# AB955; RRID:AB\_ 307338
  LEAF Purified anti-mouse GM-CSF antibody (clone MP1--22E9)         BioLegend                                                                              Cat\# 505408; RRID:AB_315384
  PerCP/Cy5.5 anti-human CD14 (clone 36D3)                           BioLegend                                                                              Cat\# 367110; RRID:AB_2566712
  PE-TR anti-human CD16 (clone 3G8)                                  ThermoFisher                                                                           Cat\# MHCD1617; RRID:AB_1464937
  PE anti-human MerTK (clone 590H11G1E3)                             BioLegend                                                                              Cat\# 367608; RRID:AB_2566401
  BV711 anti-mouse/human CD11b (clone M1/70)                         BioLegend                                                                              Cat\# 101242; RRID:AB_2563310
  APC anti-human CD68 (Clone Y1/82a)                                 BioLegend                                                                              Cat\# 333810; RRID:AB_2275735
  BUV395 anti-mouse/human CD45 (clone HI30)                          BD Biosciences                                                                         Cat\# 563791; RRID:AB_2744400
  APC Annexin V apoptosis Detection Kit with 7-AAD                   BioLegend                                                                              Cat\# 640930
  Biological Samples                                                                                                                                        
  Endomyocardial Biopsies                                            University of Texas Health Science Center                                              <https://www.texasheart.org/>; <https://www.uth.edu/>
  Giant Cell Endomyocardial Biopsies Sample                          University of Tubingen                                                                 <https://uni-tuebingen.de/en/university.html>
  Chemicals, Peptides, and Recombinant Proteins                                                                                                             
  0.05% Trypsin-EDTA (1x)                                            Life Technologies                                                                      Cat\#25300--054
  MyHCa614--629                                                      GenScript                                                                              Cat\#639666--1
  Protease, Type XIV: Bacterial, From *Streptomyces griseus*         Sigma-Aldrich                                                                          Cat\#P5147--5G
  Deoxyribonuclease I                                                Worthington                                                                            Cat\#LS002139
  Collagenase II                                                     Worthington                                                                            Cat\#LS004177
  Pertussis Toxin from *Bordetella pertussis*                        List Biological Laboratories, Inc.                                                     Cat\#180, \#181
  Mycobacterium Tuberculosis Des. H37 Ra                             BD                                                                                     231141
  L-Glutamine                                                        Corning Inc.                                                                           Cat\#25--005-CI
  Freund's Adjuvant Complete                                         Sigma                                                                                  Cat\#F5881--10X10ML
  Sodium Pyruvate                                                    Sigma                                                                                  Cat\#S8636
  Antibiotic antimycotic solution (100x)                             Corning Inc.                                                                           Cat\#30--004-CI
  CellStripper                                                       Corning Inc.                                                                           Cat\#25--05-CI
  1M HEPES Buffer pH7.3                                              Quality Biological                                                                     Cat\#118--089--721
  Histopaque-1119                                                    Sigma                                                                                  Cat\#11191--6X100ML
  HIstopaque-1077                                                    Sigma                                                                                  Cat\#10771--6X100ML
  Bovine Serum Albumin                                               Sigma                                                                                  Cat\#A3608--100G
  ACK Lysing Buffer                                                  Quality Biological                                                                     Cat\#118--156--721
  MEM NON-Essential Amino Acid solution 100x                         Sigma-Aldrich                                                                          Cat\# M7145
  Lysis Buffer RLT Plus                                              QIAGEN                                                                                 Cat\#1053393
  EDTA                                                               Corning Inc.                                                                           Cat\#46--034-CI
  Fluoresbrite Plain YG 0.5 Micron Microspheres (2.5%Solids Latex)   Polysciences, Inc.                                                                     Cat\#17152
  Differential Quik Stain Solution C Xanthene Dye                    Polysciences, Inc.                                                                     Cat\#24606C-250
  Differential Quik Stain Solution A Fixative                        Polysciences, Inc.                                                                     Cat\#24606A-250
  Differential Quik Stain Solution B Blue Dye                        Polysciences, Inc.                                                                     Cat\#24606B-250
  Liposomal Clodronate                                               Clodrosome                                                                             Cat\#CLD-8909
  DMEM (1X)                                                          GIBCO                                                                                  Cat\#11995--065
  Anti-Ly6G Microbead Kit mouse                                      Miltenyi Biotec                                                                        Cat\#130--092--332
  Anti-CD11b Microbead Kit mouse/human                               Miltenyi Biotec                                                                        Cat\#130--049--601
  TRIzol reagent                                                     ThermoFisher                                                                           Cat\#15596026
  Heat Inactivated Fetal Bovine Serum                                ThermoFisher                                                                           Cat\#A3840001
  Recombinant Murine GM-CSF                                          Peprotech                                                                              Cat\#315--03
  DAPI Solution (1mg/ml)                                             ThermoFisher                                                                           Cat\#62248
  SafeFix II All-Purpose Fixative                                    ThermoFisher                                                                           Cat\#23--042600
  Evans Blue                                                         Sigma                                                                                  Cat\#E21129
  Sudan Black B                                                      Sigma                                                                                  Cat\#199664--25G
  BD Cytofix Fixation Buffer                                         BD Biosciences                                                                         Cat\# 554655
  CountBright absolute counting beads                                Invitrogen                                                                             Cat\# C36850
  Anti-MoCD-16/CD32                                                  eBioscience                                                                            Cat\#14--0161--86
  Forane Liquid for inhalation 100ml                                 Baxter                                                                                 Cat\#1001936040
  Buprenorphine (1mg/ml)                                             ZooPharm                                                                               Cat\#BZ8069317
  Succinyl Choline (20mg/ml)                                         Hospira, Inc.                                                                          Cat\# 81--081-EV
  High Capacity cDNA reverse Transcription Kit                       FisherScientific                                                                       Cat\#4368814
  SYBR Green PCR Master Mix                                          BioRad                                                                                 Cat\#4367659
  CFSE CellTrace Cell Proliferation Kit                              Invitrogen                                                                             Cat\# C34554
  D-Glucose Anhydrous                                                Amresco                                                                                Cat3 0188--1KG
  Magnesium Sulfate                                                  Amresco                                                                                Cat\# E797--500G
  Potassium Chloride                                                 Sigma                                                                                  Cat\# 60130--250G
  Taurine                                                            Sigma                                                                                  Cat3T0625--100G
  Tween 200                                                          Sigma                                                                                  Cat3 P1379--500ML
  Sodium Chloride                                                    Fisher BioReagents                                                                     Cat\#M-11615
  Sodium Bicarbonate                                                 Amresco                                                                                Cat\# 0865--1KG
  Sodium phosphate dibasic heptahydrate, ACS regent                  Sigma                                                                                  Cat\#S9390--500G
  Potassium Phosphate monobasic                                      Sigma                                                                                  Cat\#P9791--100G
  Heparin sodium salt from porcine intestinal mucosa                 Sigma                                                                                  Cat\#H3393--10Ku
  Triton X-100                                                       Sigma                                                                                  Cat\#T9284--100ML
  2,3-butanedione                                                    Sigma                                                                                  Cat\# B0753--100G
  RNeasy Micro Kit                                                   QIAGEN                                                                                 Cat\#74004
  GeneChip 3′ IVT Pico Kit                                           ThermoFisher                                                                           Cat\#902789
  Live/Dead Fixable Far Red Dead Cell Stain Kit                      Invitrogen                                                                             Cat\# L10120
  Live/Dead Fixable Aqua Dead Cell Stain Kit                         ThermoFisher                                                                           Cat\# L34966
  Critical Commercial Assays                                                                                                                                
  Mouse MER ELISA Kit                                                Abcam                                                                                  Cat\#AB210572
  Human MER ELISA Kit                                                Abcam                                                                                  Cat\#AB119604
  Clariom S Assay, mouse                                             ThermoFisher                                                                           Cat\#902930
  Deposited Data                                                                                                                                            
  Raw and analyzed microarray data                                   This paper                                                                             GEO: GSE118861
  Experimental Models: Organisms/Strains                                                                                                                    
  Mouse: BALB/cJ                                                     The Jackson Laboratory                                                                 Cat\# 000651
  Mouse: CByJ.SJL(B6)-*Ptprc*^a^/J                                   The Jackson Laboratory                                                                 Cat\# 006584
  Mouse: IL-17Ra^−/−^ (BALB/c)                                       Amgen Inc.; Children's Hospital University of Pittsburg Medical Center (Dr. J Kolls)   [@R94]; [@R91]
  Mouse: IL-17Ra^−/−^ (CByJ.SJL(B6)-*Ptprc*^a^/J)                    This Paper                                                                             N/a
  Oligonucleotides                                                                                                                                          
  *Ccl2* forward primer (5′ to 3′): TTAAAAACCTGGATCGGAACCAA          This paper                                                                             N/A
  *Ccl2* reverse primer (5′ to 3′): GCATTAGCTTCAGATTTACGGGT          This paper                                                                             N/A
  *Hprt* forward primer (5′ to 3′): TCAGTCAACGGGGGACATAAA            This paper                                                                             N/A
  *Hprt* reverse primer (5′ to 3′): GGGGCTGTACTGCTTAACCAG            This paper                                                                             N/A
  Software and Algorithms                                                                                                                                   
  FlowJo                                                             FlowJo                                                                                 RRID:SCR_008520
  *Cyt*                                                              [@R1]; [@R11]                                                                          <https://systemsbiology.columbia.edu/center-for-computational-biology-and-bioinformatics-c2b2>
  MATLAB                                                             MATLAB                                                                                 RRID:SCR_001622
  PRISM                                                              PRISM                                                                                  RRID:SCR_005375
  Partek Genomics Suite                                              Partek Genomics Suite                                                                  RRID:SCR_011860
  Spotfire                                                           TIBCO                                                                                  RRID:SCR_008858

###### Highlights

-   Cardiac fibroblasts facilitate differentiation of Ly6C^hi^ and Ly6C^lo^ monocytes

-   IL-17A trans-signaling inhibits Ly6C^lo^ monocyte-to-macrophage differentiation

-   IL-17A trans-signaling increases MerTK shedding on monocyte-derived macrophages

-   IL-17A trans-signaling promotes monocyte-derived macrophages to be proinflammatory
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